According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

Researchers at National Jewish Health and colleagues have completed the first study comparing lung macrophages in multiple ...

In STAT's "jealousy list" for 2024, STAT staffers explain what makes a selection of stories they read in other publications ...

A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...

Changing Futures, a nonprofit dedicated to advancing cystic fibrosis (CF) research, will hold a polar plunge at noon New Year ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.